Introduction
Nicardipine is a dihydropyridine calcium channel inhi bitor possessing antihypertensive and arterial vasodila tor propertiesl,2). Pharmacokinetic studies for in travenous administration in man reported a biphasic decline with a terminal half life of 1-5 hr3-9>. A sust ained-release capsule (Perdipine LA®) has gained widespread clinical use. However, terminal rate con stants for the oral administration of uncoated tablets') or sustained-release capsules'()), are much smaller than for intravenous administration.
Different rate constants during the terminal phase may be due to the sensitivity of the assay procedures for each sampling period, which in turn provide data to de termine the area under the concentration-time curve (AUC). Since it would be useful to determine the phar macokinetics of nicardipine using standard techniques, the terminal phase of orally and intravenously ad ministered nicardipine was examined to confirm the exis tence of a similar small rate constant. Differences in the terminal decay of nicardipine have a seriously affect measurement of its bioavailability. This paper describes the determination of the constants for nicardipine after bolus injection and constant infusion and gives accurate estimates on the bioavailability after oral administration by AUCpo/AUCIV correcting for dose which exhibits the linear pharmaciokinetics.
Methods

Subject
One healthy subject (32-year-old woman) was used in this study on receipt of her informed consent. No other medication was taken at least 2 weeks prior to and dur ing the study. Subject had normal renal and liver func tion.
Materials
Nicardipine was obtained from Yamanouchi Phar maceuticals (Japan) as the hydrochloride salt in either a sustained-release capsule (Perdipine LA®) containing 40 mg or in an intravenous solution (Perdipine solut ion") containing 1 mg/ml.
Study Protocol
Perdipine solution® for bolus injection was diluted with saline to yield a volume of 9 ml, which contained 1.05 mg nicardipine. This diluted solution was ad ministered over 2 min. Venous blood samples were col lected from the arm in heparinized glass tubes at 0.12 , 0.23, 0.37, 0.73, 1.1, 1.9, 3.0 and 4.0 hr after infusion.
After washout interval of one week, a Perdipine LA® 40 mg capsule was administered with 100 ml water at AM 9 : 00 after the subject fasted for 10 hr. Blood sam ples were collected in heparinized glass tubes at 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 hr.
After a lapse of two weeks, a Perdipine LAO 40 mg capsule was given twice daily (at AM 9 : 00 and PM 9 : 00) with 100 ml water for 10.5 days, and the multiple doses were consisted of the 21st dosing. Blood samples were collected at AM 9 : 00 right before each dosing. At the 8th and the 20th dosing interval during this multiple dosing, the additional blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 10 and 12 hr after the 8th and 20th dos ing. Blood samples were collected at 12, 14, 15, 18, 20 and 36 hr after the last dose.
A constant rate intravenous infusion using a TERU FUSION Syringe Pump (Model: STC 531, TERMO Ltd.) was used to administer a 1.27 mg/hr nicardipine dose for 3 hr into the subject's left arm. Venous blood samples were collected from the right arm in heparinized glass tubes at 0, 0. Plasma was separated from blood by centrifugation, and was kept frozen at -20°C until analysis .
Analytical Method Plasma concentrations of nicardipine were analyzed by a capillary column GC-ECD procedure"). The sen sitivity was 1 ng/ml.
Data Analysis
Intravenous Data Plasma data were analyzed by a computer program , MULTI").
1) Bolus infusion Data
The plasma concentrations of nicardipine following bo lus injection were fitted to bi-exponential equation (1) .
Ct represents plasma nicardipine concentration at time t. Al and A2 are the hybrid constants, and a and /3 are the hybrid constants.
2) Constant rate infusion Data For constant rate infusion1) plasma concentrations of nicardipine were fitted to tri-exponential equations (2) and (3) .
The A, B and C are hybrid constants, and a , /3 and y are hybrid constant. Ko represents the infusion rate .
with T the infusion time.
Oral Data
Rate constants were calculated using a semi logarithmic plot of plasma nicardipine concentrations.
Calculation of Absorption Rate and Reconstruc tion of Plasma Nicardipine
Concentration-Time Profile after Single Oral Dosing from Intravenous Data Bolus intravenous injection data and oral single dose data were analyzed using deconvolution analysis") to cal culate absorption rates. However, long intervals be tween sampling times are inadequate for this analysis. To make up for these long intervals, the SPLINE func tion program16) was used and the interval between the sampling points was reassigned as every 0.1 hr. Using the absorption rate during the absorption phase, the con volution analysis program17) was used to reconstruct simulation curve of the protracted rate constant at termi nal phase of oral single dose.
Calculation of Bioavailability AUC was calculated by the trapezoidal rule. Assuming the pharmacokinetics of nicardipine is linear, the absolute bioavailability was calculated using equation (4) .
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Results and Discussion
The plasma nicardipine concentration vs. time curve after a bolus 1.05 mg injection is shown in Fig. 1 . Nicardipine levels in plasma were below the detection limit at 4 hr after administration. A steep log linear decline was obtained from 0.12 to 1 hr. After that, a more protracted decay was observed from 1 to 3 hr. A good fit was obtained to the bi-exponential equation (1) by the Damping-Gauss-Newton method (weighting was 1/Cp2). A value was 2.92 hr-1 for a and 0.148 hr-1 for /3. These data are in agreement with other reports6,8).
A plasma profile after a single oral dose of Perdipine LA® 40 mg (as nicardipine hydrochloride) capsule is shown in Fig. 2 . This graph was made up for using SPLINE function every 0.1 hr-'. The calculated line represents a good fitting. Two peaks were observed. The first peak appeared at 0.5 hr and the second 4 hr af ter administration. This phenomenon can be explained by the difference in absorption rates between the two type of granules which are dissolved in either the stomach or intestineW. A semilogarithmic plot of plas ma concentrations from 4 to 24 hr displayed a two-phase decline. The hybrid constants in the terminal phase were 0.264 hr-1 and 0.0221 hr-1. From the reported sin gle dose data18) of Perdipine LA® capsule, the rate con stant during the two-decline terminal phase were calcu lated. The hybrid constants during the terminal phase were 0.868 and 0.0613 hr-1. These parameters are in agreement with our obtained parameters. Using decon volusion analysis, the absorption rate was calculated (Fig. 3) . In human studies, it is next to impossible to set up sufficiently frequent blood sampling points in ord er to get accurate pharmacokinetic parameters, however frequent blood sampling points were obtained. In par ticular, frequent blood sampling points during absorp tion phase are very important. These blood sampling (1) to the bolus injection data. A time course curve of the plasma nicardipine concen tration vs. time after multiple oral doses is shown in Fig. 4 . A plateau level was reached at 4th dose. The steady-state minimum plasma concentrations were main tained at about 4-9 ng/ml. Plasma nicardipine profile wi thin the 8th dosing interval showed one peak of concen tration 39.2 ng/ml. For the 20th dose, plasma concentra tions showed two peaks: a first peak was 31.6 ng/ml and a second 25.9 ng/ml. Differential absorption due to vary granule signs can explain one peak at a first dosing inter val. However, the double peak of the 20th have been due to food effect since no control was made for food for the multiple dose regimen. The semilogarithmic plot of the plasma concentrations vs. time at the last dose from 12 to 36 hr showed a two phase decline and hybrid con stants were 0.138 hr-1 and 0.0414 hr-1. The values were closely similar to these obtained for the terminal phase of single oral dose.
Plasma nicardipine concentration at 1.27 mg/hr for 3 hr is shown in Fig. 5 . After infusion stopped, the concen trations declined rapidly from 3 to 7 hr as was seen in the bolus injection. Subsequently, a more protracted decay with the more gentle slope was observed.
A good fit of the data was obtained to the tri-exponential equa tions (equation (2) and (3)) by Damping-Gauss-New ton method (weighting was 1/Cp2). A comparison of hybrid constants after intravenous ad ministration of bolus and constant rate infusion is shown in Table I . The y-value was about 1/5 that of the average ,6. In another report at a higher dose of 5 mg/hr for 3 hr reported only a bi-exponential decay was ob served. However, that study measured plasma concen trations for only 7 hr which would have been insufficient to detect the y--phases). Therefore, )-phase might have been found if more plasma samples had been taken as in our study. This y-value was very close to the protracted rate constants which were observed after oral adminis tration. (2) and (3) to the constant rate infusion data. To confirm the y-phase during the terminal phase af ter oral dosing, the plasma nicardipine concentration time profile of single oral dose was reconstructed by con volution analysis. The absorption rate from 0 to 8.5 hr, which was calculated by deconvolution analysis, was used as absorption phase data. In the presence and ab sence of y-phase, the profiles were different (Fig. 6) . Equation (1) and y-value of constant infusion were used. The C value (the hybrid constant for the y-value when assuming tri-exponential decay) was estimated as 0.313 ng/ml by the smallest sum of square division (weight was 0) from the bolus intravenous injection data. Only in the presence of the y-value, the remarka ble biphasic terminal phase was observed. This result ex plained the rate constant which was not observed during the absorption phase.
Nicardipine has an arterial vasodilator properties in the brain12). Slow transfer into the brain and slow back diffusion from cerebrospinal fluid (CSF) might explain the appearance of the y-phase only for the constant rate infusion and for the oral dosing. Nicardipine concentra tion in CSF have not been reported. Wagner5) reported that the elimination phase after oral administration was linear with 30 mg to 120 mg nicardipine a day as a hydrochloride salt. On the other hand it was reported that similar clearance values were obtained at two levels of bolus dose injection (0.01 mg/ kg and 0.02 mg/kg) 3). Steady-state average plasma con centrations (40 to 150 mg as hydrochloride salt a day) were shown to exhibit linear kinetics10>. In this study, each a value and 0 value were roughly equal whether 1.05 mg bolus injection or constant rate infusion at 1.27 mg for 3 hr. The ratio of AUC0__ at a single PO dose to AUCDos ng Interval at multiple doses was about 1. There fore, the pharmacokintics of nicardipine was assumed to be linear. Bioavailability values calculated by equation (4) are listed on Table II . Area values calculated for bolus injec tion data (about 20%) represented twice those for con stant rate infusion data. In the case of nicardipine bolus injection, the low sensitivity of the assay failed to detect the y-phase. In order to detect the y-phase after bolus in jection, the dose would have to be high. A high-dose nicardipine bolus injection produces side effects, which are flushing and palpitation4). Therefore, high dose bo lus injection is very dangerous and has to be avoided. It is no report that the presence or absence of a y-phase misleads estimation of bioavailability data. However, when the human bioavailability studies are performed for nicardipine, it is important to administer nicardipine solution using constant rate infusion which can avoid the dangerous side effects of bolus injection yet still provide detection of the "y-phase".
